About Us

About Advaite

Advaite Inc. is a Malvern, PA headquartered biotech company focused on developing novel therapeutics and diagnostics to help patients suffering from a variety of debilitating diseases, primarily within the oncology space. The word ‘Advaite’ means ‘one without a second’, unrivaled or unique. At Advaite, we aspire to be just that.

Advaite operates a high complexity CLIA laboratory and state-of the-art R&D facility in Malvern, PA; Advaite is continuously innovating, developing and commercializing point-of-care tests to address this pandemic and help impact large populations.

Advaite develops a therapeutic and diagnostic solution for cancer. The pipelined therapeutic is ADV100 is a drug that has significant anti-inflammatory and anti-fibrotic actions. It thus has therapeutic potential in reducing ocular surface disease secondary to tear deficiency induced by conditions such as ocular GVHD. ADV300 is a novel AMES Negative HDAC6 inhibitor for the treatment of multiple cancers. ADV200 is a panel of four tear fluid biomarkers (BM1-4) that serve as indicators of processes that contribute to the pathophysiology of ocular surface diseases.

Innovative Therapeutics

ADV300 is a novel AMES Negative HDAC6 inhibitor for the treatment of multiple cancers. Histone Deactylases (HDACs) can modulate a multitude of cellular processes and are a part of the regulation of cellular pathways involved in anti-tumor immune responses. Selective inhibition of HDAC6 slows tumor growth in various cancer models. Many prominent selective HDAC6 inhibitors are limited to pre-clinical research because they display mutagenic characteristics from the AMES test. ADV300 shows high potency against HDAC6, no mutagenicity and low cytotoxicity. Currently being evaluated in preclinical studies.